Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Current Assets (2016 - 2025)

Plus Therapeutics has reported Current Assets over the past 16 years, most recently at $15.2 million for Q4 2025.

  • Quarterly Current Assets rose 188.46% to $15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.2 million through Dec 2025, up 188.46% year-over-year, with the annual reading at $15.2 million for FY2025, 188.46% up from the prior year.
  • Current Assets was $15.2 million for Q4 2025 at Plus Therapeutics, down from $17.6 million in the prior quarter.
  • Over five years, Current Assets peaked at $22.1 million in Q1 2022 and troughed at $4.2 million in Q1 2024.
  • The 5-year median for Current Assets is $14.4 million (2023), against an average of $14.2 million.
  • Year-over-year, Current Assets tumbled 69.09% in 2024 and then surged 227.85% in 2025.
  • A 5-year view of Current Assets shows it stood at $19.7 million in 2021, then increased by 10.61% to $21.8 million in 2022, then tumbled by 54.93% to $9.8 million in 2023, then plummeted by 46.52% to $5.3 million in 2024, then surged by 188.46% to $15.2 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Current Assets are $15.2 million (Q4 2025), $17.6 million (Q3 2025), and $9.2 million (Q2 2025).